Zimmer Biomet acquires CD Diagnostics

Zimmer Biomet Holdings Inc. today announced that it has acquired CD Diagnostics.

"Our acquisition of CD Diagnostics cements our leadership and competitive advantage in musculoskeletal diagnostics, strengthens our Signature Solutions offering, and advances our mission to provide comprehensive musculoskeletal health care," Zimmer Biomet Group President Dan Williamson said. "As value-based health care replaces fee-for-service models, there will be a growing need for diagnostics that can either prevent or minimize costly complications, or personalize the course of treatment to speed up recovery time and optimize the patient experience and, ultimately, the patient's outcome."

Zimmer Biomet and CD Diagnostics collaborated in 2012 for the development and marketing of diagnostics in musculoskeletal health care, which produced the Synovasure Periprosthetic Joint Infection (PJI) test.

"I formed CD Diagnostics to solve the frustrating problem of diagnosing PJI and the complications associated with misdiagnosis, including the pain and incremental costs-of-care following joint replacement surgery," CD Diagnostics Scientific Founder Dr. Carl Deirmengian said. "As a leader and visionary in musculoskeletal healthcare, Zimmer Biomet is the ideal partner to leverage our expertise in biomarker detection and immunoassay development, and to elevate the value of diagnostics in the treatment of musculoskeletal conditions."

The financial terms of the deal have not yet been disclosed.